Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Yamamoto, Shohei  [Clear All Filters]
Journal Article
Zhang P, He F, Bai J, Yamamoto S, Chen S, Zhang L, Sheng M, Zhang L, Guo Y, Man N, et al. Chromatin regulator Asxl1 loss and Nf1 halpoinsufficiency cooperate to accelerate myeloid malignancy. J Clin Invest. 2018.
Matsuno R, Toyama D, Akiyama K, Isoyama K, Shiozawa E, Yamamoto S. Killer-cell immunoglobulin-like receptor ligand mismatch cord blood transplantation in high-risk neuroblastoma. Pediatr Int. 2019.
Ebihara Y, Yamamoto S, Mochizuki S, Tsukada M, Taya Y, Kawakita T, Kato S, Ooi J, Takahashi S, Tojo A, et al. Pneumothorax in an early phase after allogeneic hematopoietic stem cell transplantation. Hematol Rep. 2013;5(2):34-5.
Yamamoto S, Kato M, Watanabe K, Ishimaru S, Hasegawa D, Noguchi M, Hama A, Sato M, Koike T, Iwasaki F, et al. Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome. Bone Marrow Transplant. 2021.
Yamamoto S, Otsu M, Matsuzaka E, Konishi C, Takagi H, Hanada S, Mochizuki S, Nakauchi H, Imai K, Tsuji K, et al. Screening of Drugs to Treat 8p11 Myeloproliferative Syndrome Using Patient-Derived Induced Pluripotent Stem Cells with Fusion Gene CEP110-FGFR1. PLoS One. 2015;10(3):e0120841.
Ueki H, Ogawa C, Goto H, Nishi M, Yamanaka J, Mochizuki S, Nishikawa T, Kumamoto T, Nishiuchi R, Kikuta A, et al. TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia. Int J Hematol. 2024.